PMC6530425_01
MR.I T1 (a) progression under nivolumab monotherapy before start of nivolumab and ipilimumab; (b) partial remission under nivolumab and ipilimumab after 2 cycles; (c) ongoing stable disease 2 years after start of combination therapy and 7 months after end of treatment.
fonc-09-00403-g0001.jpg
PMC6530425_01_fonc-09-00403-g0001.jpg
F1
Unfortunately, in August 2016 after 11 administrations of nivolumab local progression was confirmed by routine follow up and radiologic scans (Figure 1a). In January 2017, following two cycles, MRI of the neck confirmed a partial remission (size reduction of more than 50%) (Figure 1b) and therapy was continued. CT and MRI scans in July and October 2018 confirmed ongoing stable disease without any signs of tumor progression (Figure 1c). Consequently, therapy has not been reinitiated, yet.